QUICK ANSWER
Separate genuine candidates from marketing categories
The catalogue includes ligandrol/LGD-4033, RAD140, ostarine/MK-2866, andarine/S4 and YK-11, which WADA 2026 lists as SARM examples. MK-677, SR9009 and GW-501516/cardarine are not SARMs.
01 · IDENTITY MAP
Catalogue identity map
SARM candidate
Human muscle-wasting research exists; no FDA approval and no bodybuilding proof
SARM candidate
Short healthy-men trial found lean-mass and hormonal/lipid signals; no established long-term benefit
SARM candidates
Insufficient human performance evidence; no FDA approval
Listed by WADA as a SARM/other anabolic agent
Extremely limited human evidence; FDA reported a stroke case involving a tested YK-11 product, without establishing every product or single-cause attribution
Ghrelin-receptor agonist / GH secretagogue
Not a SARM
PPAR-delta agonist candidate
Not a SARM
REV-ERB-related experimental compound
Not a SARM
Catalogue names do not authenticate supplier identity, composition, quality or authorization.
02 · HUMAN EVIDENCE
Biological signals exist; approved indications do not
Short trial in healthy men
A 21-day study found exposure-related lean-mass increases plus suppression of total testosterone, SHBG and HDL. It was too small and short to establish long-term safety or health outcomes.
Trials and case reports
A review covering 1,447 SARM-exposed people reported DILI, rhabdomyolysis and tendon rupture, with ALT elevations in some trials.
Labels did not establish identity
Only 52% contained a SARM, 41% matched the labeled amount, and 25% contained undeclared substances.
03 · SAFETY BOUNDARY
Material risks and uncertainties
- Drug-induced liver injury, including hospital-treated cases
- Testosterone/gonadotropin suppression, sexual dysfunction, testicular shrinkage and infertility
- Lipid, blood-pressure and cardiovascular concerns, including FDA heart-attack/stroke warnings
- Psychiatric, sleep, tendon and rhabdomyolysis reports
- Contamination, undeclared drugs, wrong amounts and multi-compound mixtures
Regulatory and sport boundary
FDA treats bodybuilding SARMs as unapproved drugs, not approved dietary supplements; “research use only” does not establish legal human use, safety or quality. This review does not verify Thai FDA authorization for catalogue products. WADA 2026 prohibits SARMs including andarine, enobosarm, LGD-4033, RAD140, S-23 and YK-11 at all times under S1.2.
04 · FAQ
Frequently asked questions
What does SARM mean?
Selective androgen receptor modulator is a class of candidates affecting androgen-receptor signaling, not one molecule.
Are SARMs safer than steroids?
That is not established. Tissue-selectivity is a development goal, not immunity from liver, hormone, lipid, cardiovascular, fertility or product-quality risks.
Do ostarine and ligandrol have human studies?
Some limited human research exists, but it is not FDA approval or evidence for bodybuilding/performance use.
Are MK-677, cardarine and SR9009 SARMs?
No. Their primary mechanisms differ from androgen-receptor modulation.
Does research use only prove quality?
No. Internet-product analyses found frequent identity and amount discrepancies.
Are SARMs allowed in sport?
No. WADA 2026 lists SARMs under S1.2 and prohibits them at all times.
05 · SOURCES & SCOPE
Primary and authoritative references
- FDA — Bodybuilding products and SARM safety warning (2 December 2025)
- FDA — Andarine and ostarine recall / unapproved-drug warning
- LGD-4033 randomized trial in 76 healthy men — PMID 22459616
- Systematic review of SARM safety — PMID 37218811
- Analysis of 44 internet products marketed as SARMs — PMID 29183075
- WADA — 2026 Prohibited List
Educational evidence and regulatory summary only. Not diagnosis, treatment, prescribing, product authentication, dosing, preparation or administration guidance. No external medical reviewer. Verify current exact-product labels and local regulatory records.